NCT00460460终止1 期
A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 75
- 试验地点
- 3
研究概览
简要总结
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with AML, a certain type of ALL, NHL and MM
- •certain types of cancer of the lymph nodes
- •certain types of leukemias (blood cancers)
- •disease has or will fail with other treatments
- •relatively good overall health other than your cancer
排除标准
- •poor bone marrow function (not producing enough blood cells)
- •serious heart conditions
- •poor liver or kidney function
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
Safety and Tolerability Study of AZD7762 in Combination With GemcitabineSolid TumorsAdvanced Solid MalignanciesCancerNCT00937664AstraZeneca24
终止
1 期
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918Cancer,Solid TumorsAdvanced Solid MalignanciesNCT00733031AstraZeneca75
已完成
1 期
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid TumorsNeoplasmsNCT00389389AstraZeneca75
已完成
1 期
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursNeoplasmsNCT02952248Boehringer Ingelheim110
终止
1 期
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT02347228Oneness Biotech Co., Ltd.21